Securities code: Sino Biological Inc(301047) securities abbreviation: Sino Biological Inc(301047) Announcement No.: 2022022 Sino Biological Inc(301047)
About profit distribution in 2021
And announcement of the plan for converting capital reserve into share capital
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sino Biological Inc(301047) (hereinafter referred to as "the company") held the 13th meeting of the first board of directors and the 12th meeting of the first board of supervisors on February 25, 2022, deliberated and adopted the proposal on the company's plan for profit distribution and conversion of capital reserve into share capital in 2021. The relevant matters are hereby announced as follows: I Profit distribution and capital reserve converted into share capital plan in 2021
According to the audit of Zhitong Certified Public Accountants (special general partnership), the net profit of the parent company in 2021 was 70004581513 yuan and the net profit in the consolidated statements was 72001367111 yuan; As of December 31, 2021, the accumulated undistributed profit of the parent company was 181400064889 yuan, and the balance of capital reserve was 485295477106 yuan; The accumulated undistributed profit in the consolidated statements is 177524472176 yuan, and the balance of capital reserve is 485295477106 yuan.
Based on the company's sustained and steady profitability, good financial condition and good expectations for future development, and considering the company's sufficient capital reserve, combined with the company's development strategy, development stage and relatively small capital stock scale, in order to optimize the company's capital structure, enhance stock liquidity, and fully consider the interests and reasonable demands of small and medium-sized investors, Taking into account the return of shareholders and the development of the company, under the condition of ensuring the healthy and sustainable development of the company, the company formulates the plan for profit distribution and conversion of capital reserve into share capital in 2021 as follows:
Based on 68 million shares of the company's total share capital as of December 31, 2021, a cash dividend of 100 yuan (including tax) will be distributed to all shareholders for every 10 shares, a total of 68 million yuan (including tax) will be distributed, and the remaining accumulated undistributed profit of 109524472176 will be carried forward for annual distribution in the future without bonus shares; At the same time, the capital reserve is used to increase 9 shares for every 10 shares to all shareholders, with a total of 61.2 million shares. After the increase, the total share capital of the company is 129.2 million shares.
After the disclosure of the 2021 profit distribution and capital reserve converted into share capital plan and before its implementation, if the company's share capital changes, it will be adjusted accordingly according to the principle that the total amount of distribution remains unchanged.
2、 Relevant review and approval procedures
1. Opinions of the board of directors
The board of directors of the company considered and approved this matter. For details, see the announcement on the resolution of the 13th meeting of the first board of directors disclosed on cninfo.com on the same day.
2. Opinions of independent directors
The independent directors of the company have expressed their independent opinions on this matter. For details, see the independent opinions of independent directors on matters related to the 13th board of directors of the company disclosed on cninfo.com on the same day.
3. Opinions of the board of supervisors
The board of supervisors of the company reviewed and approved this matter. For details, please refer to the announcement on the resolution of the 12th meeting of the first board of supervisors disclosed on cninfo.com on the same day.
3、 Other instructions
The plan for profit distribution and conversion of capital reserve into share capital in 2021 needs to be submitted to the company's 2021 annual general meeting for deliberation and approval before implementation. This matter is still uncertain. Please pay attention to investment risks.
4、 Documents for future reference
1. Resolutions of the 13th meeting of the first board of directors of the company;
2. Resolutions of the 12th meeting of the first board of supervisors of the company;
3. Independent opinions of independent directors on matters related to the 13th meeting of the first board of directors.
It is hereby announced.
Sino Biological Inc(301047) board of directors February 25, 2022
